Human neutrophil peptides and complement factor Bb in pathogenesis of acquired thrombotic thrombocytopenic purpura

Haematologica

Volumn 101, Issue 11, 2016, Pages 1319-1326

  Cao, Wenjing ^a   Pham, Huy P ^a   Williams, Lance A ^a   McDaniel, Jenny ^a   Siniard, Rance C ^a   Lorenz, Robin G ^a   Marques, Marisa B ^a   Long Zheng, X ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; COLCHICINE; COMPLEMENT COMPONENT C4D; COMPLEMENT MEMBRANE ATTACK COMPLEX; CORTICOSTEROID; CXCL1 CHEMOKINE; ECULIZUMAB; PLATELET DERIVED GROWTH FACTOR BB; RITUXIMAB; VON WILLEBRAND FACTOR CLEAVING PROTEINASE; ALPHA DEFENSIN; BIOLOGICAL MARKER; HUMAN NEUTROPHIL PEPTIDE 1; HUMAN NEUTROPHIL PEPTIDE 2; HUMAN NEUTROPHIL PEPTIDE 3;

ARTICLE; BLOOD CULTURE; COMORBIDITY; COMPLEMENT ACTIVATION; COMPLEMENT ALTERNATIVE PATHWAY; COMPLEMENT CLASSICAL PATHWAY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE EXACERBATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMATOCRIT; HUMAN; HUMAN TISSUE; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOASSAY; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKOCYTE ACTIVATION; LEUKOCYTE DIFFERENTIAL COUNT; MAJOR CLINICAL STUDY; MALE; MORTALITY RATE; PLASMA; PLASMA EXCHANGE; THROMBOCYTE COUNT; THROMBOTIC THROMBOCYTOPENIC PURPURA; ADULT; BLOOD; IMMUNOLOGY; INNATE IMMUNITY; PATHOLOGY; PURPURA, THROMBOTIC THROMBOCYTOPENIC;

ADULT; ALPHA-DEFENSINS; BIOMARKERS; COMPLEMENT FACTOR B; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNITY, INNATE; MALE; PURPURA, THROMBOTIC THROMBOCYTOPENIC;

EID: 84994607433     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2016.149021     Document Type: Article

References (46)

1. Hosler GA, Cusumano AM, Hutchins GM. Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome are distinct pathologic entities. A review of 56 autopsy cases. Arch Pathol Lab Med. 2003; 127 (7): 834-839.
2. Bell WR, Braine HG, Ness PM, Kickler TS. Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients. N Engl J Med. 1991; 325 (6): 398-403.
3. Tsai HM. Thrombotic thrombocytopenic purpura: a thrombotic disorder caused by ADAMTS13 deficiency. Hematol Oncol Clin North Am. 2007; 21 (4): 609-632.
4. Zheng XL. ADAMTS13 and von Willebrand Factor in Thrombotic Thrombocytopenic Purpura Annu Rev Med. 2015; 66: 211-225.
5. Lotta LA, Wu HM, Mackie IJ, et al. Residual plasmatic activity of ADAMTS13 is correlated with phenotype severity in congenital thrombotic thrombocytopenic purpura. Blood. 2012; 120 (2): 440-448.
6. Barbot J, Costa E, Guerra M, et al. Ten years of prophylactic treatment with freshfrozen plasma in a child with chronic relapsing thrombotic thrombocytopenic purpura as a result of a congenital deficiency of von Willebrand factor-cleaving protease. Br J Haematol. 2001; 113 (3): 649-651.
7. Casina V, Hu WB, Mao JH, et al. High Resolution Epitope Mapping by HX MS Reveals the Pathogenic Mechanism and a Possible Therapy for Autoimmune TTP Syndrome. PNAS. 2015; 112 (31): 9620-9625.
8. Mise K, Ubara Y, Matsumoto M, et al. Long term follow up of congenital thrombotic thrombocytopenic purpura (Upshaw-Schulman syndrome) on hemodialysis for 19 years: a case report. BMC Nephrol. 2013; 14: 156.
9. Fujimura Y, Matsumoto M, Isonishi A, et al. Natural history of Upshaw-Schulman syndrome based on ADAMTS13 gene analysis in Japan. J Thromb Haemost. 2011; 9 Suppl 1: 283-301.
10. Zheng XL, Kaufman RM, Goodnough LT, Sadler JE. Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura. Blood. 2004; 103 (11): 4043-4049.
11. Pillai VG, Bao J, Zander CB, et al. Human neutrophil peptides inhibit cleavage of von Willebrand factor by ADAMTS13: a potential link of inflammation to TTP. Blood. 2016; 128 (1): 110-119.
12. Ruiz-Torres MP, Casiraghi F, Galbusera M, et al. Complement activation: the missing link between ADAMTS-13 deficiency and microvascular thrombosis of thrombotic microangiopathies. Thromb Haemost. 2005; 93 (3): 443-452.
13. Westwood JP, Langley K, Heelas E, Machin SJ, Scully M. Complement and cytokine response in acute Thrombotic Thrombocytopenic Purpura. Br J Haematol. 2014; 164 (6): 858-866.
14. Chapin J, Eyler S, Smith R, Tsai HM, Laurence J. Complement factor H mutations are present in ADAMTS13-deficient, ticlopidine-associated thrombotic microangiopathies. Blood. 2013; 121 (19): 4012-4013.
15. George JN. How I treat patients with thrombotic thrombocytopenic purpura: 2010. Blood. 2010; 116 (20): 4060-4069.
16. Kokame K, Nobe Y, Kokubo Y, Okayama A, Miyata T. FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay. Br J Haematol. 2005; 129 (1): 93-100.
17. Raife TJ, Cao W, Atkinson BS, et al. Leukocyte proteases cleave von Willebrand factor at or near the ADAMTS13 cleavage site. Blood. 2009; 114 (8): 1666-1674.
18. Deford CC, Reese JA, Schwartz LH, et al. Multiple major morbidities and increased mortality during long-term follow-up after recovery from thrombotic thrombocytopenic purpura. Blood. 2013; 122 (12): 2023-2029; quiz 2142.
19. Korkmaz S, Keklik M, Sivgin S, et al. Therapeutic plasma exchange in patients with thrombotic thrombocytopenic purpura: a retrospective multicenter study. Transfus Apher Sci. 2013; 48 (3): 353-358.
20. Fuchs TA, Kremer Hovinga JA, Schatzberg D, Wagner DD, Lammle B. Circulating DNA and myeloperoxidase indicate disease activity in patients with thrombotic microangiopathies. Blood. 2012; 120 (6): 1157-1164.
21. Mikes B, Sinkovits G, Farkas P, et al. Elevated plasma neutrophil elastase concentration is associated with disease activity in patients with thrombotic thrombocytopenic purpura. Thromb Res. 2014; 133 (4): 616-621.
22. Noris M, Mescia F, Remuzzi G. STEC-HUS, atypical HUS and TTP are all diseases of complement activation. Nat Rev Nephrol. 2012; 8 (11): 622-633.
23. Zheng X, Pallera AM, Goodnough LT, Sadler JE, Blinder MA. Remission of chronic thrombotic thrombocytopenic purpura after treatment with cyclophosphamide and rituximab. Ann Intern Med. 2003; 138 (2): 105-108.
24. Li D, Xiao J, Paessler M, Zheng XL. Novel recombinant glycosylphosphatidylinositol (GPI)-anchored ADAMTS13 and variants for assessment of anti-ADAMTS13 autoantibodies in patients with thrombotic thrombocytopenic purpura. Thromb Haemost. 2011; 106 (5): 947-958.
25. Dong JF, Moake JL, Nolasco L, et al. ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions. Blood. 2002; 100 (12): 4033-4039.
26. Moake JL, Rudy CK, Troll JH, et al. Unusually large plasma factor VIII: von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Engl J Med. 1982; 307 (23): 1432-1435.
27. Bernardo A, Ball C, Nolasco L, et al. Platelets adhered to endothelial cell-bound ultra-large von Willebrand factor strings support leukocyte tethering and rolling under high shear stress. J Thromb Haemost. 2005; 3 (3): 562-570.
28. Chauhan AK, Motto DG, Lamb CB, et al. Systemic antithrombotic effects of ADAMTS13. J Exp Med. 2006; 203 (3): 767-776.
29. Gandhi C, Khan MM, Lentz SR, Chauhan AK. ADAMTS13 reduces vascular inflammation and the development of early atherosclerosis in mice. Blood. 2012; 119 (10): 2385-2391.
30. Turner NA, Moake J. Assembly and activation of alternative complement components on endothelial cell-anchored ultralarge von Willebrand factor links complement and hemostasis-thrombosis. PloS one. 2013; 8 (3): e59372.
31. Corken A, Russell S, Dent J, Post SR, Ware J. Platelet glycoprotein Ib-IX as a regulator of systemic inflammation. Arterioscler Thromb Vasc Biol. 2014; 34 (5): 996-1001.
32. Downing LJ, Wakefield TW, Strieter RM, et al. Anti-P-selectin antibody decreases inflammation and thrombus formation in venous thrombosis. J Vasc Surg. 1997; 25 (5): 816-827.
33. Song ZF, Chen DY, Du B, Ji XP. Poly (ADPribose) polymerase inhibitor reduces heart ischaemia/reperfusion injury via inflammation and Akt signalling in rats. Chin Med J (Engl). 2013; 126 (10): 1913-1917.
34. Zhao L, Lu W. Defensins in innate immunity. Curr Opin Hematol. 2014; 21 (1): 37-42.
35. Horn M, Bertling A, Brodde MF, et al. Human neutrophil alpha-defensins induce formation of fibrinogen and thrombospondin-1 amyloid-like structures and activate platelets via glycoprotein IIb/IIIa. J Thromb Haemost. 2012; 10 (4): 647-661.
36. Chaly YV, Paleolog EM, Kolesnikova TS, et al. Neutrophil alpha-defensin human neutrophil peptide modulates cytokine production in human monocytes and adhesion molecule expression in endothelial cells. Eur Cytokine Netw. 2000; 11 (2): 257-266.
37. Higazi AA, Ganz T, Kariko K, Cines DB. Defensin modulates tissue-type plasminogen activator and plasminogen binding to fibrin and endothelial cells. J Biol Chem. 1996; 271 (30): 17650-17655.
38. Kougias P, Chai H, Lin PH, et al. Neutrophil antimicrobial peptide alpha-defensin causes endothelial dysfunction in porcine coronary arteries. J Vasc Surg. 2006; 43 (2): 357-363.
39. Quinn K, Henriques M, Parker T, Slutsky AS, Zhang H. Human neutrophil peptides: a novel potential mediator of inflammatory cardiovascular diseases. Am J Physiol Heart Circ Physiol. 2008; 295 (5): H1817-1824.
40. Zhao H, Yan H, Yamashita S, et al. Acute ST-segment elevation myocardial infarction is associated with decreased human antimicrobial peptide LL-37 and increased human neutrophil peptide-1 to 3 in plasma. J Atheroscler Thromb. 2012; 19 (4): 357-368.
41. Sthoeger ZM, Bezalel S, Chapnik N, Asher I, Froy O. High alpha-defensin levels in patients with systemic lupus erythematosus. Immunology. 2009; 127 (1): 116-122.
42. Panyutich AV, Panyutich EA, Krapivin VA, Baturevich EA, Ganz T. Plasma defensin concentrations are elevated in patients with septicemia or bacterial meningitis. J Lab Clin Med. 1993; 122 (2): 202-207.
43. Cohen JA, Brecher ME, Bandarenko N. Cellular source of serum lactate dehydrogenase elevation in patients with thrombotic thrombocytopenic purpura. J Clin Apher. 1998; 13 (1): 16-19.
44. Groeneveld TW, Ramwadhdoebe TH, Trouw LA, et al. Human neutrophil peptide-1 inhibits both the classical and the lectin pathway of complement activation. Mol Immunol. 2007; 44 (14): 3608-3614.
45. Reti M, Farkas P, Csuka D, et al. Complement activation in thrombotic thrombocytopenic purpura. J Thromb Haemost. 2012; 10 (5): 791-798.
46. Wu TC, Yang S, Haven S, et al. Complement activation and mortality during an acute episode of thrombotic thrombocytopenic purpura. J Thromb Haemost. 2013; 11 (10): 1925-1927.